LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
LIVN•LivaNova’s third-quarter revenue rose 9.9% to $393.1 million, beating estimates, while adjusted EPS of $1.23 also topped consensus. The company raised its 2026 revenue growth and adjusted diluted EPS guidance.
1. Quarterly results
LivaNova reported third-quarter revenue of $393.1 million, up 9.9% and above the $381.07 million analyst consensus. Adjusted EPS was $1.23, compared with the $1.06 consensus; EPS was $0.11.
2. Segment performance
Cardiopulmonary revenue rose 10.9%, driven by consumables demand, Essenz Perfusion System sales and favorable realized price. Neuromodulation revenue increased 11.1%, with growth across all regions driven by higher volume and favorable realized price. The company said its new oxygenator manufacturing line began operational production.
3. Updated outlook
LivaNova raised its 2026 revenue growth guidance to 9%-10% on a constant-currency basis, from 8%-9%, and its adjusted diluted EPS outlook to $4.40-$4.50, from $4.30-$4.40. It maintained adjusted free cash flow guidance of $140 million to $160 million.
